Country: Канада
Језик: Енглески
Извор: Health Canada
DIMETHYL FUMARATE
GLENMARK PHARMACEUTICALS CANADA INC.
L04AX07
DIMETHYL FUMARATE
240MG
CAPSULE (DELAYED RELEASE)
DIMETHYL FUMARATE 240MG
ORAL
15G/50G
Prescription
MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS
Active ingredient group (AIG) number: 0154210002; AHFS:
APPROVED
2021-10-04
_Pr_ _GLN-DIMETHYL FUMARATE (Dimethyl Fumarate Delayed Release Capsules) _ _ _ _ _ _Page 1 of 40 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR GLN-DIMETHYL FUMARATE dimethyl fumarate delayed-release capsules delayed-release capsules, 120 mg and 240 mg, oral Antineoplastic and Immunomodulating Agents Glenmark Pharmaceuticals Canada Inc. 1600 Steeles Ave. West, Suite 407 Concord, ON L4K 4M2 Date of Initial Authorization: October 04, 2021 Date of Revision: November 2, 2023 Submission Control No: 277311 _Pr_ _GLN-DIMETHYL FUMARATE (Dimethyl Fumarate Delayed Release Capsules) _ _ _ _ _ _Page 2 of 40 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS 11/2023 8 ADVERSE REACTIONS, 8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data 11/2023 10 CLINICAL PHARMACOLOGY, 10.2 Pharmacodynamics 11/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ....................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics .............................................................................................................. 4 1.2 Geriatrics .............................................................................................................. 4 2 CONTRAINDICATIONS .............................................................................................. 4 4 DOSAGE AND ADMINISTRATION ............................................................................ 4 4.1 Dosing Considerations ......................................................................................... Прочитајте комплетан документ